IO Biotech

IO Biotech EBIT/Assets

Delisted·Sep 22, 2026

The Operating Income to Assets Ratio (EBIT/Assets) of IO Biotech (IOBT) as of Nov 20, 2026 is -140.59 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -60.67 % — a change of 131.72% (lower).

EBIT/Assets

-140.59 %

YoY

131.72%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of IO Biotech is 2024 -140.59 % . Operating Income to Assets Ratio (EBIT/Assets) of IO Biotech was 2023 -60.67 % . It decreases by 131.72% lower compared to the previous year.

The IO Biotech EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2019
-105.20 USD
Jan 1, 2020
-179.46 USD
Jan 1, 2021
-18.55 USD
Jan 1, 2022
-47.05 USD
Jan 1, 2023
-60.67 USD
Jan 1, 2024
-140.59 USD
The IO Biotech EBIT/Assets history
YEAREBIT/AssetsYoY
-140.59 %+131.72%
-60.67 %+28.95%
-47.05 %+153.64%
-18.55 %-89.66%
-179.46 %+70.59%
-105.20 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IO Biotech Stock analysis

What does IO Biotech do? IO Biotech, Inc. develops immune modulating cancer therapies using its T-win technology platform. The Company focuses on product candidates that target immunosuppressive proteins like IDO and PD-L1, aiming to disrupt tumor-induced immunosuppression. Its lead candidate, IO102-IO103, is designed to address multiple pathways regulated by these proteins. The firm's pipeline includes therapies leveraging T-win to target the tumor microenvironment (TME). IO Biotech's revenue model is based on the development and potential commercialization of its product candidates. The company generates income through partnerships with pharmaceutical firms for the development and licensing of its therapies. These partnerships are formed with entities interested in advancing immune modulating cancer treatments. The target market includes pharmaceutical companies seeking innovative cancer therapy solutions. The firm's technology platform, T-win, is central to its business strategy. By targeting key immunosuppressive proteins such as IDO and PD-L1, IO Biotech addresses a critical need in cancer treatment. Its lead product candidate, IO102-IO103, is positioned to disrupt multiple immunosuppressive pathways, offering a novel approach to cancer therapy. IO Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IO Biotech stock

Operating Income to Assets Ratio (EBIT/Assets) of IO Biotech is -140.59 % in 2024.

Operating Income to Assets Ratio (EBIT/Assets) of IO Biotech changed from -60.67 % to -140.59 %, representing a 131.72% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) IO Biotech since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s IO Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — IO Biotech

All Key Metrics — IO Biotech